SOCS5 contributes to temozolomide resistance in glioblastoma by regulating Bcl-2-mediated autophagy
ABSTRACTTemozolomide (TMZ) is the primary chemotherapeutic drug for treating glioblastoma (GBM); however, the final clinical outcome is considerably limited by the poor response and resistance to TMZ. Although autophagy is thought to be associated with chemotherapy resistance and cancer cell surviva...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2022-06-01
|
Series: | Bioengineered |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/21655979.2022.2081463 |